Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 161

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 161
---
 |
| Series AA Preferred |     | All Officers and Directors as a Group |     |                                           | 334 |     |            | 100 | % |

based on 15,007 shares outstanding

| Title of Class      |     | Name and Address of Beneficial Owner  |     | Amount and Nature of Beneficial Ownership |        |     | Percentage |     |   |
| Series NC Preferred |     | David R. Koos                         |     |                                           |        |     |            |     |   |
|                     |     | c/o Regen Biopharma, Inc.             |     |                                           | 15,007 |     |            | 100 | % |
|                     |     | 4700 Spring Street St 304             |     |                                           |        |     |            |     |   |
|                     |     | La Mesa CA 91942                      |     |                                           |        |     |            |     |   |
| Series NC Preferred |     | All Officers and Directors as a Group |     |                                           | 15,007 |     |            | 100 | % |

| 127 |

SALES OF UNREGISTERED SECURITIES

July 1, 2025 to August 21, 2025

On July 28, 2025 Regen Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with CFI Capital LLC (“CFI”), pursuant to which CFI purchased a 6% convertible promissory Note (the “Note”) from the Company in the principal amount of $130,000 of which $13,000 was retained by CFI through an Original Issue Discount. The Note is due and payable on July 28, 2026.

The Holder of this Note is entitled, at its option, at any time after the 6th monthly anniversary of this Note, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock (the “Common Stock”) at a price (“Conversion Price”) for each share of Common Stock equal to 60% of the lowest trading price of the Common Stock as reported on the OTC Markets on which the Company’s shares are then traded or any exchange up-on which the Common Stock may be traded in the future (the “Exchange”), for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company.

The Note was issued pursuant to